|
|
|
Registry of biomedical companies:
[3] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 467 active entries
6330 Nancy Ridge Drive, Ste 106
San Diego, 92121
United States of America, California
Toll free: (866) 623-8105
Phone: (858) 623-8105
Fax: (858) 623-8109
E-Mail:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.
Description:
InVivoScribe Technologies, Inc. (IVS) is a privately-held reagents manufacturing company located in San Diego, that controls exclusive-licensed patents to technologies and biomarkers that have proven clinical utility. Our GMP manufacturing facility is complemented by a CLIA- and CAP-accredited molecular diagnostics laboratory located in San Diego, California, and a sales and distribution center in La Ciotat, Provence, France.
Our companies are dedicated to improving the quality of healthcare worldwide by providing high quality, reliable, cutting-edge tools for personalized molecular medicine and molecular diagnostics. Other proprietary technologies include research use tools that improve the reliability and reproducibility of data mining and analysis using proprietary in vivo cDNA synthesis technologies.
InVivoScribe provides a comprehensive selection of PCR-based gene rearrangement, chromosome translocation, and gene mutation testing reagents and controls. Our selection of RUO and IVD products are used to identify, stratify, and monitor leukemias, lymphomas and other lymphoproliferative disease.
As a contract research organization, InVivoScribe provides standardized tests and clinical service to assist in the development of pharmaceutical agents and devices. In addition, we produce GMP reagents for specific analytic platforms.
InVivoScribe's gene rearrangement products and biomarker tests are covered by exclusive-licensed patents. The corporation and its subsidiaries are debt-free and profitable.
Selected Categories:
Last update of this entry: March 15, 2011
|